文献速递白血病

CDX2增强子重定位与UBTF::ATXN7L3融合定义高危B祖细胞急性淋巴细胞白血病亚型

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2022-01-01

研究对3221例初诊和177例复发B-ALL进行全基因组、转录组测序及增强子定位和染色质拓扑分析,发现17例初诊和5例复发患者具有CDX2去调控和UBTF::ATXN7L3融合,该亚型多见于年轻女性,CD10阴性、IgM阳性,56.3%具有高危特征。

要点

  • CDX2/UBTF亚型由RAG异常激活导致,表现为CDX2去调控和UBTF::ATXN7L3融合。
  • 该亚型患者以年轻女性为主,中位年龄35岁,免疫表型为CD10阴性、IgM阳性。
  • 16例可评估患者中9例(56.3%)具有高危特征,包括复发或诱导缓解后MRD>1%。

核心结论

  • CDX2去调控、UBTF::ATXN7L3重排的B-ALL是年轻成人高危白血病亚型,需要新的治疗方法。

研究设计与样本

  • 研究纳入初诊B-ALL 3221例和复发B-ALL 177例,进行肿瘤RNA测序,并采用全基因组测序检测突变、结构变异和拷贝数变异,以及HiChIP进行组蛋白H3K27乙酰化和染色质环分析。

主要发现

  • 共发现17例初诊和5例复发B-ALL具有独特的基因表达谱,以及两种由异常RAG激活导致的普遍且独特的基因组改变。
  • 13q12.2处PAN3下游局灶性缺失导致CDX2被PAN3增强子去调控,17q21.31处UBTF外显子18-21局灶性缺失导致嵌合融合UBTF::ATXN7L3。
  • 部分病例还有PAX5基因重排和表达增高,这在B-ALL中不常见。
  • 患者更常见为女性和年轻成人,中位年龄35岁(范围12-70岁),免疫表型为CD10阴性和免疫球蛋白M阳性。
  • 16例有已知临床反应的患者中,9例(56.3%)具有高危特征,包括复发(4例)或缓解诱导结束时微小残留病>1%(5例)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcriptome sequencing has identified multiple subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL) of prognostic significance, but a minority of cases lack a known genetic driver. Here, we used integrated whole-genome (WGS) and -transcriptome sequencing (RNA-seq), enhancer mapping, and chromatin topology analysis to identify previously unrecognized genomic drivers in B-ALL. Newly diagnosed (n = 3221) and relapsed (n = 177) B-ALL cases with tumor RNA-seq were studied. WGS was performed to detect mutations, structural variants, and copy number alterations. Integrated analysis of histone 3 lysine 27 acetylation and chromatin looping was performed using HiChIP. We identified a subset of 17 newly diagnosed and 5 relapsed B-ALL cases with a distinct gene expression profile and 2 universal and unique genomic alterations resulting from aberrant recombination-activating gene activation: a focal deletion downstream of PAN3 at 13q12.2 resulting in CDX2 deregulation by the PAN3 enhancer and a focal deletion of exons 18-21 of UBTF at 17q21.31 resulting in a chimeric fusion, UBTF::ATXN7L3. A subset of cases also had rearrangement and increased expression of the PAX5 gene, which is otherwise uncommon in B-ALL. Patients were more commonly female and young adult with median age 35 (range,12-70 years). The immunophenotype was characterized by CD10 negativity and immunoglobulin M positivity. Among 16 patients with known clinical response, 9 (56.3%) had high-risk features including relapse (n = 4) or minimal residual disease >1% at the end of remission induction (n = 5). CDX2-deregulated, UBTF::ATXN7L3 rearranged (CDX2/UBTF) B-ALL is a high-risk subtype of leukemia in young adults for which novel therapeutic approaches are required.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kimura S, Montefiori L, Iacobucci I, et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022. PMID: 35192684. doi:10.1182/blood.2022015444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。